During a live event, Jeffrey V. Matous, MD, discussed flexible dosing and the need to expand use in community practices for ...

Multiple myeloma causes lytic or osteolytic lesions, which are areas of damage caused by cancerous plasma cells blocking normal bone growth. While painful, they can be managed. Multiple myeloma is ...

Explore the innovative subcutaneous delivery of isatuximab for multiple myeloma, enhancing patient experience and treatment ...

We've come a long way since the first immunomodulatory agent was approved for use in myeloma. ... Pathology & Lab Medicine. Pediatrics. Plastic Surgery. Psychiatry. Public Health. Pulmonary Medicine.

Karolinska University Hospital has, for the first time in Sweden, begun preparations to treat a patient with multiple myeloma ...

Karolinska University Hospital has, for the first time in Sweden, begun preparations to treat a patient with multiple myeloma ...

In fact, 1 in 5 myeloma patients are diagnosed with the disease only because they’ve gone to the doctor for routine medical exams and had lab tests that revealed telltale changes in blood or ...

Iberdomide plus dexamethasone was generally safe and showed meaningful clinical activity in heavily pretreated patients with multiple myeloma, including in disease that was refractory to ...

Sandia National Laboratories has joined the National Semiconductor Technology Center as part of efforts to re-establish the U.S. as a leader in semiconductor production.. The Albuquerque, New ...

According to clinical guidelines, high-risk myeloma patients should receive intensified treatment regimens. However, heterogeneity in cli ...